Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • A strong welfare state mitigates the impact of the Great Recession

  • Costs to treat bleeding strokes increases 10 years later

  • For brain hemorrhage, risk of death lower at high-volume hospitals

  • Nursery places for three-year-olds: introduction of free entitlement did not deliver long-term benefits for children?s development, new research finds

  • Boosting use of multi-sensory environments in dementia care

  • Clot dissolver tpa's tardy twin could aid in stroke recovery

  • Exposure therapy appears helpful in treating patients with prolonged grief

  • Omega 3 can help children with ADD, experts say

  • Music therapy reduces depression in children, adolescents

  • Teens whose parents exert more psychological control have trouble with closeness, independence

  •